The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on Giant Cell Arteritis

Updates on Giant Cell Arteritis

March 19, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“This is a clear failure of that immune checkpoint,” she said. Erythrocyte sedimentation rate testing can show that PD-L1 expression on dendritic cells inversely correlates with inflammatory markers in GCA patients. When researchers treated bio-engineered mice with a checkpoint inhibitor to block PD-L1, “we see that it breaks the immune tolerance of the vessel wall.3 If we break the checkpoint with this treatment, we get vigorous GCA disease in these arteries. Checkpoint inhibition also accelerates inflammatory cytokine production.” Treatment raises PD-1 levels, increases pro-inflammatory transcription factors, and enhances IFN-γ, IL-17A and IL-21, she said. It also unleashes T cell immunity, thickens the intima and dramatically increases microvascular angiogenesis in the adventitia.

You Might Also Like
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
Explore This Issue
March 2018
Also By This Author
  • MIF Cytokine May Impact Inflammation, Bone Formation in Ankylosing Spondylitis

Tocilizumab, an IL-6 inhibitor, is approved by the U.S. Food & Drug Administration to treat GCA, but unanswered questions, including whether biomarkers for disease activity are lost after therapy blocks IL-6 & if the tissue-protective functions of acute phase proteins are also blocked by treatment, are important for GCA patients, said Dr. Weyand.

Diagnosis & Therapy

To diagnose GCA, rheumatologists typically evaluate the temporal artery, especially in patients with cranial manifestations, said Tanaz A. Kermani, MD, MS, FACP, assistant professor of medicine and director of the Vasculitis Program at the University of California, Los Angeles. Biopsy may detect disease symptoms even weeks after treatment is initiated, but it is invasive, she said. High-resolution magnetic resonance imaging (MRI) of scalp arteries shows some promise as an alternative non-invasive modality for initial GCA diagnosis, and ultr

Dr. Kermani

Dr. Kermani

asound may also be helpful, but the sensitivity of both MRI and ultrasound diminish after patients start treatment.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A new approach being studied is the fast-track clinic, where rheumatologists promptly evaluate any patients with suspected GCA, including use of ultrasound.5 If GCA is indicated, patients begin treatment right away, said Dr. Kermani. Data from these clinics has shown a dramatic decrease in vision loss, but more prospective data is needed on this approach, she said.

In evaluation, rheumatologists may overlook GCA’s possible extracranial manifestations, such as large artery stenosis or aortic involvement, said Dr. Kermani. Physical examination has poor sensitivity in diagnosing large-vessel vasculitis, so angiography or positron emission tomography (PET) may be used to find lesions in these vessels.6,7

Careful evaluation is important, because a significant portion of GCA patients may develop large-vessel manifestations, especially aortic aneurysms even 10 years after diagnosis.8

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“This is an important implication for our patients. They may no longer be following up with rheumatology because they may be off treatment, but this is a late complication of the disease,” she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Meeting Reports, Vasculitis Tagged With: ACR/ARHP Annual Meeting, giant cell arteritis (GCA)Issue: March 2018

You Might Also Like:
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
  • Varicella Zoster Virus May Cause Giant Cell Arteritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)